RE: Synairgen and Soton Uni24 Mar 2020 13:30
From the RNS....18th March
On cv19
Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and Trial Chief Investigator, commented: “We are facing an unprecedented health challenge with COVID-19 which desperately requires the rapid development of new therapeutic strategies. There are a limited number of candidate new treatments available and so it is vital we can rapidly generate high quality evidence on the role of these in COVID-19 patients. The UK research delivery and regulatory teams have worked incredibly effectively to enable this world leading trial to achieve approvals so rapidly which has enabled our motivated and highly expert team of researchers to get this vital study running straight away.”
Update on SNG001 Phase II trial in COPD
Synairgen is now close to completing a Phase II study in chronic obstructive pulmonary disease (COPD) patients with confirmed respiratory viral infections and pre-existing significant impairment of lung function. With 109 out of a target 120 participants already dosed, this trial has been paused to minimise the chance of vulnerable patients being exposed to further infection risk and to minimise distraction for respiratory staff in the UK hospitals and GP sites conducting the trial, who will be at the forefront in dealing with patients suffering from COVID-19. We are currently exploring ways to adapt the trial to enable patients in the pre-treatment pool to be dosed if they become infected with SARS-CoV-2.
Early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.
https://www.synairgen.com/news/
From NHS news release, 9th March
Prof Tom Wilkinson’s research group has renewed a long-standing collaboration with AstraZeneca to understand the mechanisms driving the development of chronic obstructive pulmonary disease (COPD).
Building on a four year collaboration between the two organisations, this renewed agreement will provide Prof Wilkinson’s group with funding for the next phase of the collaboration between AstraZeneca and the University of Southampton, a leading centre in understanding disease mechanisms of COPD and airway infection.
Establishing a well characterised cohort of patients with COPD has allowed these scientists to investigate differences in gene expression which drive the immune response to viral infection in COPD.
I think AZN are going to fund the next part of the COPD trial. It’s SNG’s drug but SO Uni infrastructure and looks like AZN paying for it.
Trek
Sign In
Follow the stocks
